2022 AUA Annual Meeting Highlights: Prostate Cancer

To better meet the educational needs of urologists and urologic healthcare providers, the AUA gathered from a variety of sources, including comprehensive literature searches and membership surveys to determine where gaps exist in the knowledge, proficiency, and practice in regards to prostate cancer. 

Acknowledgements 

The AUA Office of Education thanks the companies who support continuing education of physicians. The AUA recognizes the following companies for providing educational grant support:

  • Astellas
  • Exact Sciences Corporation
  • Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC
  • Lantheus Medical Imaging
  • Pfizer, Inc.
  • Sanofi Genzyme

Target Audience

  • Urologists
  • Urologists in training
  • Non-Physician providers involved in Urology

Learning Objectives

At the conclusion of the activity, participants will be able to:

  1. Explain the research and clinical publications from the past year on prostate cancer concerning risk stratification, screening, and biopsy methods.
  2. Highlight recent guideline updates in management of clinically localized prostate cancer.
  3. Describe the various disease states comprising advanced prostate cancer and advancement in management.
  4. Discuss new treatment available for patients with newly diagnosed M1 prostate and new treatment available for patients with M0 metastatic castrate-resistant prostate cancer.
  5. Counsel men with BRCA1/2 mutations, Lynch syndrome, and other key inherited syndromes regarding their prostate cancer risk, and utilize genetic testing results to improve outcomes for patients with metastatic prostate cancer.
  6. Describe which molecular tests can be performed on prostatectomy specimens and differentiate between somatic and germline mutations.
  7. Identify biomarkers used for initial diagnosis, risk stratification, posttreatment, and advanced disease.

 

Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Non-Physician Participation
Course opens: 
10/01/2022
Course expires: 
10/31/2023
Rating: 
0

COI Review Work Group Disclosures

PDF icon COI Review Work Group Disclosures_2022.pdf

AUA Staff have nothing to disclose.

All relevant financial relationships have been mitigated.

Author(s)

Stephen Boorjian, MD

has a financial relationship (Consultant or Advisor (Oncology)) with Prokarium;.
has a financial relationship (Consultant or Advisor (Oncology)) with ArTara;.
has a financial relationship (Consultant or Advisor (Oncology)) with FerGene;.
has a financial relationship (Consultant or Advisor (General Urology)) with Ferring;.

William Catalona, MD

has a financial relationship (Consultant or Advisor (Oncology)) with deCODE genetics;.
has a financial relationship (Consultant or Advisor (Oncology)) with Beckman-Coulter Incorporated;.
has a financial relationship (Consultant or Advisor (Oncology)) with Beckman-Coulter Incorporated;.

Michael Cookson, MD,MHA

has a financial relationship (Consultant or Advisor (Oncology)) with Nonagen Bioscience Corp.;.
has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Clinical Education Alliance, LLC;.
has a financial relationship (Consultant or Advisor (Oncology)) with Myovant Sciences;.
has a financial relationship (Consultant or Advisor (Oncology)) with Prokarium;.
has a financial relationship (Consultant or Advisor (Oncology)) with Pfizer;.
has a financial relationship (Consultant or Advisor (Oncology)) with Bayer Healthcare Pharmaceuticals;.
has a financial relationship (Health Publishing (Oncology)) with BioPharm Communications;.
has a financial relationship (Consultant or Advisor (Oncology)) with TesoRx Pharma LLC;.
has a financial relationship (Consultant or Advisor (Oncology)) with MJH LifeSciences;.
has a financial relationship (Consultant or Advisor (Oncology)) with Pacifice Edge Diagnostics;.
has a financial relationship (Consultant or Advisor (Oncology)) with Astellas Pharma, Inc.;.

Douglas Dahl, MD

has a financial relationship (Investment Interest (Specialty Not Specified)) with Bristol Myers Squibb;.
has a financial relationship (Investment Interest (Specialty Not Specified)) with Abbvie;.
has a financial relationship (Investment Interest (General Urology)) with Tak Pharmaceuticals;.
has a financial relationship (Investment Interest (Oncology)) with Novartis;.
has a financial relationship (Investment Interest (Specialty Not Specified)) with GlaxoSmithKline;.
has a financial relationship (Investment Interest (General Urology)) with Vertex;.
has a financial relationship (Investment Interest (Non-urology Healthcare Related)) with Roche;.
has a financial relationship (Investment Interest (Specialty Not Specified)) with Merck;.
has a financial relationship (Investment Interest (Specialty Not Specified)) with Amgen;.
has a financial relationship (Consultant or Advisor (General Urology)) with Civco;.
has a financial relationship (Investment Interest (Specialty Not Specified)) with Eli Lilly;.
has a financial relationship (Investment Interest (Specialty Not Specified)) with Johnson and Johnson;.
has a financial relationship (Investment Interest (General Urology)) with cvs;.

James Eastham, MD

has a financial relationship (Investment Interest (Specialty Not Specified)) with 3DBiopsy;.

Leonard Gomella, MD

has a financial relationship (Consultant or Advisor (Oncology)) with Lantheus;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Merck Pharmaceuticals;.
has a financial relationship (Health Publishing (Specialty Not Specified)) with Merck Manual;.
has a financial relationship (Consultant or Advisor (Oncology)) with Astra Zeneca;.
has a financial relationship (Health Publishing (Specialty Not Specified)) with Canadian Journal of Urology;.
has a financial relationship (Intellectual Property Interest (Oncology)) with Thomas Jefferson University;.
has a financial relationship (Health Publishing (Specialty Not Specified)) with Wolters Kluwer;.
has a financial relationship (Consultant or Advisor (Oncology)) with Exelixis;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with MDx Health;.
has a financial relationship (Health Publishing (Specialty Not Specified)) with McGraw Hill;.

Rachel Hastings, PA-C, MS

has no relevant financial relationships to disclose at this time.

David Jarrard, MD

has no relevant financial relationships to disclose at this time.

Lawrence Karsh, MD, FACS

has a financial relationship (Scientific Study or Trial (Oncology)) with Tavanta;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Genetech/Hoffman;.
has a financial relationship (Consultant or Advisor (Oncology)) with EMD Serono;.
has a financial relationship (Scientific Study or Trial (Specialty Not Specified)) with Hinova;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Cepheid ;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Arivan Research;.
has a financial relationship (Scientific Study or Trial (Oncology)) with FKD;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Nymox ;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Augmenix ;.
has a financial relationship (Consultant or Advisor (Oncology)) with Clovis;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Bristol Myers Squibb;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Epizyme;.
has a financial relationship (Scientific Study or Trial (Oncology)) with QED;.
has a financial relationship (Consultant or Advisor (Oncology)) with UroGPO;.
has a financial relationship (Scientific Study or Trial (Oncology)) with NeoGenomic Laboratories;.
has a financial relationship (Scientific Study or Trial (Specialty Not Specified)) with BioXcel;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Siemans;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Urogen;.
has a financial relationship (Consultant or Advisor (Oncology)) with Myovant ;.
has a financial relationship (Investment Interest (Oncology)) with 3D Biopsy ;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Precision Med;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Bayer;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Exelexis;.
has a financial relationship (Consultant or Advisor (Oncology)) with Astra-Zeneca;.
has a financial relationship (Consultant or Advisor (Oncology)) with Kiadis;.
has a financial relationship (Consultant or Advisor (Oncology)) with ABBVIE;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Veru Pharmaceuticals;.
has a financial relationship (Consultant or Advisor (Oncology)) with GenomeDx BIosciences ;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Nucleix ;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with UROGPO;.
has a financial relationship (Consultant or Advisor (Oncology)) with Pfizer;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Vaxiion;.
has a financial relationship (Consultant or Advisor (Oncology)) with OPKO;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Astellas;.
has a financial relationship (Consultant or Advisor (Oncology)) with Tolmar;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Dendreon;.
has a financial relationship (Consultant or Advisor (Oncology)) with Merck;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Genomic Health;.
has a financial relationship (Consultant or Advisor (Oncology)) with Boston Scientific;.
has a financial relationship (Consultant or Advisor (Oncology)) with Medivation;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Minomic ;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with CUSP;.
has a financial relationship (Consultant or Advisor (Oncology)) with Arivan Research;.
has a financial relationship (Consultant or Advisor (General Urology)) with Swan Valley Medical;.
has a financial relationship (Consultant or Advisor (Oncology)) with Precision Biopsy ;.
has a financial relationship (Consultant or Advisor (Oncology)) with Myriad Genetics;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Exact Sciences;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Janssen;.
has a financial relationship (Consultant or Advisor (Oncology)) with Sesen;.

Adam Kibel, MD

has a financial relationship (Consultant or Advisor (Oncology)) with AstraZeneca;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Merck;.
has a financial relationship (Consultant or Advisor (Oncology)) with Insight Diagnositics;.
has a financial relationship (Other (Oncology)) with advantagene;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Profound;.
has a financial relationship (Consultant or Advisor (Oncology)) with Exlexis;.
has a financial relationship (Consultant or Advisor (Oncology)) with General Electric;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Janssen;.
has a financial relationship (Consultant or Advisor (Oncology)) with Myovant;.
has a financial relationship (Consultant or Advisor (Oncology)) with Bayer;.
has a financial relationship (Other (Specialty Not Specified)) with Bristol-Myers Squibb;.

Stanley Liauw,

has no relevant financial relationships to disclose at this time.

Stacy Loeb, MD

has a financial relationship (Investment Interest (Non-urology Healthcare Related)) with Gilead;.

Todd Morgan, MD

has a financial relationship (Scientific Study or Trial (Oncology)) with Myriad Genetics;.
has a financial relationship (Consultant or Advisor (Oncology)) with Blue Earth;.
has a financial relationship (Consultant or Advisor (Oncology)) with Tempus;.
has a financial relationship (Consultant or Advisor (Oncology)) with Stratify Genomics;.
has a financial relationship (Scientific Study or Trial (Oncology)) with MDxHealth;.
has a financial relationship (Consultant or Advisor (Oncology)) with Myovant Biosciences;.

Alicia Morgans, MD, MPH

has a financial relationship (Consultant or Advisor (General Urology)) with Novartis;.
has a financial relationship (Consultant or Advisor (Oncology)) with Progenics ;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Astra Zeneca;.
has a financial relationship (Consultant or Advisor (General Urology)) with BMS;.
has a financial relationship (Consultant or Advisor (General Urology)) with Janssen;.
has a financial relationship (Consultant or Advisor (Oncology)) with Myriad;.
has a financial relationship (Consultant or Advisor (General Urology)) with Pfizer;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Bayer;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Genetech;.
has a financial relationship (Consultant or Advisor (Oncology)) with Clovis;.
has a financial relationship (Consultant or Advisor (Oncology)) with Lantheus;.
has a financial relationship (Consultant or Advisor (General Urology)) with Myovant;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Sanofi;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Genetech;.
has a financial relationship (Consultant or Advisor (General Urology)) with Dendreon;.
has a financial relationship (Consultant or Advisor (Oncology)) with Advanced Accelerator Applications;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Advanced Accelerator Applications;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Astellas;.
has a financial relationship (Consultant or Advisor (General Urology)) with Merck;.
has a financial relationship (Consultant or Advisor (Oncology)) with Telix;.

Judd Moul, MD,FACS

has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Sanofi-Aventis;.
has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Genomic Health;.
has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Astellas;.
has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Janssen- J and J;.
has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Blue Earth Diagnostics;.
has a financial relationship (Consultant or Advisor (Oncology)) with Tolmar;.
has a financial relationship (Health Publishing (Oncology)) with Up to Date;.
has a financial relationship (Consultant or Advisor (Oncology)) with Bayer;.
has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Exosome Dx ;.
has a financial relationship (Other (Oncology)) with Best Doctors;.
has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Dendreon;.
has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Ferring;.
has a financial relationship (Scientific Study or Trial (Oncology)) with Pfizer;.
has a financial relationship (Consultant or Advisor (Oncology)) with Theralogix;.

Robert Nadler, MD

has a financial relationship (Scientific Study or Trial (Specialty Not Specified)) with Allena ;.
has a financial relationship (Meeting Participant or Lecturer (Specialty Not Specified)) with Retrophin;.
has a financial relationship (Meeting Participant or Lecturer (Endourology/Stone Disease)) with Travere Therapeutics;.

Kristen Scarpato, MD,FACS,MPH

has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Photocure;.
has a financial relationship (Consultant or Advisor (Oncology)) with CxBladder;.
has a financial relationship (Consultant or Advisor (Oncology)) with Optum;.

Joseph Wagner, MD

has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Genomic Health;.
has a financial relationship (Consultant or Advisor (Robotic Surgery)) with Covidien;.
has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Decipher Biosciences;.

METHOD OF PARTICIPATION: 

To claim CME credit/hours of participation, the learner must read the content, complete the posttest, passing with 80% accuracy and submit the evaluation and credit request form.

Estimated time to complete this activity: 1.25 hours
Release Date: October 2022
Expiration Date: October 31, 2023

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments. 

RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint).
  • Inclusion of moderated panel discussion with unbiased moderator.
  • Publication of a parallel or rebuttal article for an article that is felt to be biased.
  • Divestiture of the relationship by faculty.
  • Recusal from controlling relevant aspects of planning.
  • Selection of alternative faculty for specific topic.

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

DISCLAIMER:

The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

REPRODUCTION PREMISSION:

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Available Credit

  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Non-Physician Participation
Please login or register to take this course.